Your browser doesn't support javascript.
Impact of COVID-19 infection on breast cancer patients: Experience in Latin-American country ACHOCC-19B study
Annals of Oncology ; 32:S1139-S1140, 2021.
Article in English | EMBASE | ID: covidwho-1432871
ABSTRACT

Background:

There are not specific information about otucomes of COVID-19 infection in patients with breast cancer. We aimed to describe the outcomes in this population in our national cohort of patients with cancer and infection for COVID-19.

Methods:

ACHOCC-19B registry is a multicenter observational study composed of a cross-sectional and a prospective cohort component. Eligibility criteria were the diagnosis of breast cancer and COVID-19 infection confirmed with RT-PCR. Follow-up of 30 days was completed. Clinical data were extracted of the multicentric register of cancer and covid-19 in Colombia (ACHOCC-19), collected from Apr 1 until Oct 31, 2020. The primary outcome was 30-day mortality from all causes and secondary outcome was asymptomatic disease. Associations between demographic or clinical characteristics and outcomes were measured with odds ratios (ORs) with 95% CIs using multivariable logistic regression.

Results:

132 patients were included(18,5% of global ACHOCC-19 cohort). 18,2% died and 25,8% was asymptomatic. In relation to the patients who died vs did not died, 68 vs 66% were > 50 years, 20 vs 10,2% with obesity, 32 vs 51,4% without comorbidities 24 vs 12% with Diabetes, 56 vs 29% arterial Hypertension, 17,75 vs 3.88% ECOG >2, 50 vs 12,5% progressive cancer, 20 vs 5,6% bacterial coinfection, 65 vs 25,2% received antibiotic and 68 vs 19% steroids for Covid-19 infection. 11.3% had severe infection and received ventilatory support and 66% died. About the asymptomatic patients 74% were > 50 years, 2,9% had obesity, 56% without comorbidities, 56% with ECOG 0 and 17,6% had metastatic disease. In the logistic regression analysis, age > 50 years (OR 2,7 95% 0,54-13,81), >2 comorbidities (OR 3,48 95% 0,26-45,71), progressive disease (OR 3,52 95% 0,47-26,57), steroids (OR 6,62 95% 1,5-26,6) and antibiotic treatment for Covid19 (OR 6,88 95% 1,60-29,76) behaved as a risk factors for mortality, but only steroids and antibiotic was statistically significant.

Conclusions:

In our study, breast cancer patients have high mortality by Covid-19 infection. Age, comorbidities, ECOG >2, progressive disease, and use of antibiotic and steroids are factors for worse prognosis. Legal entity responsible for the study The authors.

Funding:

Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Experimental Studies Language: English Journal: Annals of Oncology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Experimental Studies Language: English Journal: Annals of Oncology Year: 2021 Document Type: Article